These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15717379)

  • 1. Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2004; (407-408):2-4. PubMed ID: 15717379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.
    Cohen C
    AIDS Treat News; 2003 Apr; (390):2-5. PubMed ID: 12739473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2003 Mar; (389):2-6. PubMed ID: 12712936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2004 Sep; (405):3-6. PubMed ID: 15595150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
    Bellman P
    AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
    Eron JJ
    J Infect Dis; 2008 May; 197 Suppl 3():S261-71. PubMed ID: 18447612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly intermittent treatment: caution.
    James JS
    AIDS Treat News; 2000 Jul; (347):2-3. PubMed ID: 12170982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The latest on structured treatment interruptions.
    Proj Inf Perspect; 2000 Aug; (30):7-8. PubMed ID: 12171016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New fixed dose once-a-day combinations. Interview by John S. James.
    Cohen C
    IAPAC Mon; 2004 Nov; 10(11):414-5, 432. PubMed ID: 15744891
    [No Abstract]   [Full Text] [Related]  

  • 10. HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. James.
    Frincke J
    AIDS Treat News; 1999 Jun; (No 320):4-7. PubMed ID: 11366467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV treatment series. Treatment interruptions. Reviewing what we've learned so far.
    Staszow K
    Posit Aware; 2006; 17(3):37-40. PubMed ID: 16791962
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Assessing Patients' Preferred Treatments (APPT-1) study.
    Moyle G
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():34-6. PubMed ID: 14617402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2 low dose and treatment interruption: interview with Kendall A. Smith. Interview by John S. James.
    Smith KA
    AIDS Treat News; 1999 Oct; (No 329):1-6. PubMed ID: 11366819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment interruption: most patients could not maintain immune control.
    James JS
    AIDS Treat News; 2004; (407-408):6. PubMed ID: 15717383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).
    Marcellin F; Boyer S; Protopopescu C; Dia A; Ongolo-Zogo P; Koulla-Shiro S; Abega SC; Abé C; Moatti JP; Spire B; Carrieri MP;
    Trop Med Int Health; 2008 Dec; 13(12):1470-8. PubMed ID: 19000156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare D has big impact on HIV treatment interruptions. Decreased access to meds, six-fold increase in interruptions.
    AIDS Alert; 2008 Nov; 23(11):121-3. PubMed ID: 19043865
    [No Abstract]   [Full Text] [Related]  

  • 20. Structured treatment interruptions and treatment intensification.
    Vella S
    AIDS Clin Care; 2000 Jul; 12(7):55-7, 62. PubMed ID: 12170956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.